HomeThe Merck Access Program for KEYTRUDAPrescribing InformationMedication Guide
Additional Product(s)

Select Cancer Type for Billing Codes

NDC and Billing Codes for KEYTRUDA

Melanoma: Advanced and Adjuvant Settings

NSCLC: Advanced, Adjuvant, and Neoadjuvant and Adjuvant Settings

Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Locally Advanced and Metastatic or Unresectable, Recurrent HNSCC

Relapsed or Refractory Classical Hodgkin Lymphoma

Refractory or Relapsed PMBCL

Advanced Urothelial Cancer

High-Risk Non-Muscle Invasive Bladder Cancer

Advanced MSI-H/dMMR Cancers

Advanced MSI-H/dMMR CRC

Advanced Gastric or GEJ Adenocarcinoma

Advanced Esophageal or GEJ Carcinoma

Advanced Cervical Cancer

Hepatocellular Carcinoma

Advanced Biliary Tract Cancer

Advanced Merkel Cell Carcinoma

RCC: Advanced and Adjuvant Settings

Endometrial Carcinoma

Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced cSCC

High-Risk Early-Stage TNBC and Advanced TNBC

Selected Indications for KEYTRUDA® (pembrolizumab)

Selected Safety Information for KEYTRUDA® (pembrolizumab)

This site is intended for health care professionals in the United States, its territories, and Puerto Rico.

Merck LogoTerms of UsePrivacy PolicyCookie PreferencesAccessibilityYour Privacy ChoicesConsumer Health Data Privacy Policy

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-KEY-XXXXXX XX/XX